|
Jan 3
|
Bionano Announces $10 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
|
|
Dec 31
|
Bionano Announces Amendment to Senior Secured Convertible Debentures in Debt Restructuring that Improves Cash Runway
|
|
Dec 19
|
Bionano Announces the Publication of Stockholder Letter Regarding Support for Proxy Proposal
|
|
Oct 9
|
Bionano Genomics Inc (BNGO) Q2 2024 Earnings Call Highlights: Navigating Revenue Challenges ...
|
|
Oct 3
|
Bionano Adjourns Special Meeting of Stockholders to October 30, 2024
|
|
Aug 8
|
Bionano Genomics (BNGO) Q2 2024 Earnings Call Transcript
|
|
Aug 7
|
Bionano Reports Second Quarter 2024 Results and Highlights Recent Business Progress
|
|
Jul 23
|
Bionano Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma
|
|
Jun 20
|
Bionano Announces Software Marketing Agreement with Revvity for Newborn Sequencing Research
|
|
Jun 17
|
Bionano Laboratories Announces New Category I CPT Code for OGM Use in Hematological Malignancy Analysis
|
|
May 9
|
Bionano Genomics, Inc. (NASDAQ:BNGO) Q1 2024 Earnings Call Transcript
|
|
May 9
|
Bionano Announces Series of Major Advancements to its Suite of Computational Tools for Comprehensive Cancer Analysis
|
|
May 9
|
Q1 2024 Bionano Genomics Inc Earnings Call
|
|
May 9
|
Bionano Genomics Inc (BNGO) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ...
|
|
May 8
|
Bionano Genomics (BNGO) Q1 2024 Earnings Call Transcript
|
|
May 8
|
Bionano Reports First Quarter 2024 Results and Highlights Recent Business Progress
|
|
May 1
|
Bionano to Report First Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 8, 2024
|
|
Apr 30
|
Bionano to Present at the RBC Capital Markets 2024 Global Healthcare Conference
|
|
Apr 25
|
3 Contrarian Investments to Make Now for Massive Upside Potential
|
|
Apr 24
|
Bionano Announces Publication Showing OGM’s High Resolution Structural Variation Detection in Cancer Validated by Cas9-Directed Nanopore Sequencing
|